Please login to the form below
morphosys
This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
Under the terms of the deal, Incyte is paying MorphoSys $750m upfront, as well as making an equity investment worth $150m in the company. ... MorphoSys is also eligible to receive milestone payments worth up to $1.1bn, in addition to any royalties from
Latest news
-
J&J’s new Darzalex formulation OK’d for use in Europe
More competition could also come from MorphoSys and Takeda, which both have anti-CD38 drugs in late-stage studies for myeloma.
-
MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss
Therapy candidate was licensed in a $1bn-plus deal last year. Germany’s MorphoSys has abandoned an atopic dermatitis drug licensed by Novartis in a $1bn-plus deal last year after ... The decision to drop MOR106, a selective IL-17c inhibitor
-
FDA verdict on Sanofi’s Darzalex rival is due in April 2020
Additional competition is however looming from MorphoSys and Takeda, which each have anti-CD38 drugs in pivotal-stage testing for myeloma, while another rival is Bristol-Myers Squibb and AbbVie’s
-
GSK pushes rheumatoid arthritis antibody into phase 3
GSK acquired the rights to otilimab from MorphoSys in a 445m deal agreed in 2013, and the German biotech stands to a receive a 22m milestone payment with the start of
-
MorphoSys eyes 2020 launch for lymphoma CAR-T challenger
New trial data has set up a US filing later this year for MorphoSys’ anti-CD19 antibody tafasitamab (MOR208) – and a possible challenge to Novartis and Gilead’s CAR-T therapies. ... The L-MIND data raise the likelihood of MorphoSys attracting a
More from news
Approximately 5 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
Morphosys. One of Europe’s star performers over the last two to three years has been Germany’s Morphosys. ... Unlike many other European biotechs, Morphosys isn’t seeking a marketing partner for the launch of its lead product, and aims to go it
-
Deal Watch November 2016
acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.
-
Pharma deals in March 2015
In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an
-
Deal Watch table for August 2014
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
-
Pharma deals during August 2014
These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Pharma industry appointments
Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Dave Lemus joins Proteros as an executive board member
He has also held roles with MorphoSys and Hoffman La Roche.
-
MorphoSys appoints Dr Markus Enzelberger as CSO
He succeeds Dr Marlies Sproll who resigns. German biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation. ... Dr Gerald Moller, supervisory board chairman,
-
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team
She joins the PR firm from MorphoSys, where she was senior VP. ... She joins the Duesseldorf, Germany-based firm from MorphoSys, where she headed the corporate communications and investor relations department as senior vice president; a role that saw her
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Associate Account Director
-
Competitive Salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Medical Editor
-
Competitive Salary
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- GSK discontinues two feladilimab trials in head and neck cancer
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Live Webinar: Social Media, Wearable Technologies, and AI
- bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021
- NICE sets out plans for ‘ambitious’ five-year strategy
- WHO director-general says pandemic can be brought under control within months
- Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer
- UK-based challenge study to re-expose healthy adults to COVID-19
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...
Latest intelligence
- Don’t limit diversity to just representation in clinical trials
- What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
- Oh no… not more training
- Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Quick links
Infographics
